International Extranodal Lymphoma Study Group (ielsg)

This study tests a combination of two drugs, acalabrutinib and tafasitamab, in 26 people with marginal zone lymphoma that has not responded to or has returned after previous treatment. The goal is to see how well the combo works and how safe it is. Participants receive treatment …

This study tests whether adding zanubrutinib to standard rituximab works better than rituximab alone for people with a rare, slow-growing lymphoma of the spleen (SMZL) who haven't had treatment yet. About 122 participants will receive either the combo or rituximab alone for up to…

This phase II trial is testing a combination of two drugs, ibrutinib and rituximab, in people with untreated marginal zone lymphoma (MZL), a type of blood cancer. The study aims to see how well the treatment controls the disease and how safe it is. About 175 participants with dif…

This study tests a combination of two drugs, chlorambucil and rituximab, followed by ongoing rituximab treatment, in 112 people with MALT lymphoma (a slow-growing cancer of the lymph nodes). The goal is to see how many patients achieve complete remission. Participants receive the…

This study looks at whether people with a type of lymphoma (PMLBCL) who have no signs of active cancer on a PET scan after chemotherapy can safely skip radiation therapy. About 540 adults will be randomly assigned to either receive radiation or just be watched closely. The goal i…

This study tests a combination of the drug pembrolizumab and standard radiation for people with a rare type of lymphoma (NK/T-cell) that hasn't been treated yet and is in early stages. Participants must be unable to receive full-dose chemotherapy due to age or other health factor…

This study reviews medical records and PET scans from 496 people with marginal zone lymphoma to see how well PET scans help doctors stage the disease and predict outcomes. Researchers will compare PET results with CT scans and other tests. The goal is to better understand the rol…